According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
Several other equities analysts have also recently weighed in on RGLS. Wedbush restated a “hold” rating and issued a $1.00 price objective on shares of Regulus Therapeutics in a report on Monday, December 16th. ValuEngine downgraded Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. Regulus Therapeutics has an average rating of “Hold” and a consensus target price of $1.31.
Shares of RGLS opened at $1.27 on Tuesday. The stock has a market capitalization of $27.41 million, a price-to-earnings ratio of -0.23 and a beta of 1.57. Regulus Therapeutics has a 12 month low of $0.50 and a 12 month high of $1.74. The firm has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $0.80.
Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.26). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. On average, equities research analysts predict that Regulus Therapeutics will post -1.11 EPS for the current year.
An institutional investor recently bought a new position in Regulus Therapeutics stock. Samsara BioCapital LLC bought a new position in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 904,407 shares of the biopharmaceutical company’s stock, valued at approximately $1,131,000. Regulus Therapeutics comprises approximately 0.7% of Samsara BioCapital LLC’s holdings, making the stock its 17th largest position. Samsara BioCapital LLC owned 4.36% of Regulus Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 36.84% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Read More: Derivative
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.